HRP20190947T1 - Heterociklički spoj - Google Patents
Heterociklički spoj Download PDFInfo
- Publication number
- HRP20190947T1 HRP20190947T1 HRP20190947TT HRP20190947T HRP20190947T1 HR P20190947 T1 HRP20190947 T1 HR P20190947T1 HR P20190947T T HRP20190947T T HR P20190947TT HR P20190947 T HRP20190947 T HR P20190947T HR P20190947 T1 HRP20190947 T1 HR P20190947T1
- Authority
- HR
- Croatia
- Prior art keywords
- groups
- optionally substituted
- atoms
- group
- aromatic heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000004434 sulfur atom Chemical group 0.000 claims 10
- 125000004429 atom Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000002950 monocyclic group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims 9
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- -1 pyrrolidinylcarbonyl Chemical group 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 claims 1
- BCWPQKADGZOWMA-UHFFFAOYSA-N 2-(7-azabicyclo[2.2.1]heptan-4-yl)-6-(5-methyl-1h-pyrazol-4-yl)-1h-thieno[3,2-d]pyrimidin-4-one Chemical group N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)C23CCC(CC2)N3)=C1C BCWPQKADGZOWMA-UHFFFAOYSA-N 0.000 claims 1
- DVPJGCNYHGTCEI-QMMMGPOBSA-N 2-[(2s)-piperidin-2-yl]-6-[5-(trifluoromethyl)-1h-pyrazol-4-yl]-1h-thieno[3,2-d]pyrimidin-4-one Chemical group N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2NCCCC2)=C1C(F)(F)F DVPJGCNYHGTCEI-QMMMGPOBSA-N 0.000 claims 1
- UTNVTGOGUMLCHR-JTQLQIEISA-N 6-(5-methyl-1h-pyrazol-4-yl)-2-[(2s)-1,2,3,6-tetrahydropyridin-2-yl]-1h-thieno[3,2-d]pyrimidin-4-one Chemical group N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2NCC=CC2)=C1C UTNVTGOGUMLCHR-JTQLQIEISA-N 0.000 claims 1
- WLKJMISWXHORCR-JTQLQIEISA-N 6-(5-methyl-1h-pyrazol-4-yl)-2-[(2s)-piperidin-2-yl]-1h-thieno[3,2-d]pyrimidin-4-one Chemical group N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2NCCCC2)=C1C WLKJMISWXHORCR-JTQLQIEISA-N 0.000 claims 1
- BSUIEXGJEQMCJC-VIFPVBQESA-N 6-(5-methyl-1h-pyrazol-4-yl)-2-[(2s)-pyrrolidin-2-yl]-1h-thieno[3,2-d]pyrimidin-4-one Chemical group N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2NCCC2)=C1C BSUIEXGJEQMCJC-VIFPVBQESA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical group N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (19)
1. Spoj, naznačen time, da je predstavljen sljedećom formulom:
u kojoj
X je atom sumpora;
Y je CH;
R1 je C1-6 alkil-skupina opcionalno supstituirana s atomom (atomima) halogena;
R2 je
(1) C1-6alkil-skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana od sljedećih:
(a) 4-7-člana monociklička nearomatska heterociklička skupina koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika opcionalno supstituirana s 1 do 3 supstituenta odabrana od
(i) atoma halogena,
(ii) hidroksi-skupine,
(iii) C1-6 alkil-skupine opcionalno supstituirane s 1 do 3 supstituenta odabrana od
(aa) atoma halogena,
(bb) hidroksi-skupine,
(cc) C1-6 alkoksi-skupine, i
(dd) C6-14 aril-skupine opcionalno supstituirane s 1 do 3 C1-6 alkil-skupine;
(iv) C1-6 alkoksi-skupine,
(v) C6-14 aril-skupine opcionalno supstituirane s 1 do 3 atoma halogena,
(vi) C6-14 ariloksi-skupine,
(vii) C1-6 alkoksi-karbonil-skupine,
(viii) C1-6 alkil-karbonil-skupine,
(ix) cijano-skupine,
(x) C6-14 arilsulfonil-skupine,
(xi) karboksi-skupine,
(xii) amino-skupine opcionalno mono- ili di-supstituirane sa C1-6 alkil-skupinom (skupinama),
(xiii) 4-7-člane monocikličke nearomatske heterocikličke skupine koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika opcionalno supstituirana s okso-skupinom, i
(xiv) okso-skupine;
(b) C1-6 alkoksi-skupina,
(c) amino-skupina opcionalno mono- ili di-supstituirana sa supstituentom (supstituentima) odabranom (odabranima) od
(i) C1-6 alkil-skupine opcionalno supstituirane s 1 do 3 supstituenta odabrana od
(aa) C6-14aril-skupine opcionalno supstituirane s 1 do 3 C1-6 alkoksi-skupine,
(bb) C1-6 alkoksi-karbonil-skupine,
(cc) 4-7-člane monocikličke aromatske heterocikličke skupine koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika,
(dd) C3-8 cikloalkil-skupine opcionalno supstituirane s 4-7-članom monocikličkom aromatskom heterocikličkom skupinom koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika, i
(ee) hidroksi-skupine;
(ii) 4-7-člane monocikličke nearomatske heterocikličke skupine koja, kao
atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika opcionalno supstituirane s 1 do 3 C7-13 aralkil-skupine,
(iii) C6-14 aril-skupine opcionalno supstituirane s 1 do 3 C1-6 alkoksi-skupine, i
(iv) C3-8 cikloalkil-skupine;
(d) 5-člana ili 6-člana aromatska heterociklička skupina,
(e) C6-14 aril-skupina, i
(f) C3-8 cikloalkil-skupina opcionalno supstituirana s amino-skupinom;
(2) C6-14 aril-skupina opcionalno supstituirana s 1 do 3 atoma halogena;
(3) 4-7-člana monociklička nearomatska heterociklička skupina koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika, premoštena nearomatska heterociklička skupina ili spirociklička nearomatska heterociklička skupina, pri čemu je nearomatska heterociklička skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana od
(a) atoma halogena,
(b) C1-6 alkil-skupine opcionalno supstituirane s 1 do 3 supstituenta odabrana od
(i) hidroksi-skupine,
(ii) C1-6 alkoksi-karbonil-skupine, i
(iii) karbamoil-skupine;
(c) C6-14 ariloksi-skupine,
(d) C1-6 alkoksi-karbonil-skupine,
(e) C1-6 alkil-karbonil-skupine,
(f) C6-14 aril-skupine opcionalno supstituirane sa C1-6 alkilsulfonil-skupinom,
(g) C7-13 aralkil-skupine opcionalno supstituirane s 1 do 3 atoma halogena,
(h) hidroksi-skupine,
(i) karbamoil-skupine, i
(j) 4-7-člane monocikličke nearomatske heterocikličke skupine koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika;
(4) C2-6 alkenil-skupina opcionalno supstituirana s 1 do 3 C6-14 aril-skupine,
(5) 5-člana ili 6-člana aromatska heterociklička skupina,
(6) nearomatska heterociklil-karbonil-skupina odabrana od pirolidinilkarbonila, ili
(7) C3-8cikloalkil-skupina opcionalno supstituirana s amino-skupinom;
ili njegova sol.
2. Spoj prema zahtjevu 1, naznačen time, da
R1 je C1-6 alkil-skupina opcionalno supstituirana s 1 do 3 atoma halogena; i
R2 je
(1) aminometil-skupina opcionalno supstituirana s 1 ili 2 C1-6 alkil-skupine,
(2) 5-člana ili 6-člana nearomatska heterociklil-metil-skupina opcionalno supstituirana sa C1-6 alkil-skupinom, ili
(3) 4-7-člana monociklička nearomatska heterociklička skupina koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika, premoštena nearomatska heterociklička skupina ili spirociklička nearomatska heterociklička skupina,
ili njegova sol.
3. Spoj prema zahtjevu 2, naznačen time, da
R2 je
(1) 5-člana ili 6-člana nearomatska heterociklil-metil-skupina, ili
(2) 4-7-člana monociklička nearomatska heterociklička skupina koja, kao atom koji je konstitutivni dio prstena osim ugljikovih atoma, sadrži od 1 do 4 heteroatoma odabrana od atoma kisika, atoma sumpora i atoma dušika, premoštena nearomatska heterociklička skupina ili spirociklička nearomatska heterociklička skupina,
ili njegova sol.
4. Spoj prema zahtjevu 3, naznačen time, da
R2 je
(1) pirolidinilmetil, ili
(2) nearomatska heterociklička skupina koja je odabrana iz skupine koja se sastoji od pirolidinila, piperidinila, 1,2,3,6-tetrahidropiridila, 7-azabiciklo[2.2.1]heptanila, 2-azabiciklo[2.2.1]heptanila i 1-azabiciklo[2.2.2]oktanila, pri čemu je nearomatska heterociklička skupina opcionalno supstituirana s 1 do 3 atoma halogena,
ili njegova sol.
5. Spoj prema zahtjevu 1, naznačen time, da je to 6-(5-metil-1H-pirazol-4-il)-2-[(2S)-pirolidin-2-il]tieno[3,2-d]pirimidin-4(3H)-on, ili njegova sol.
6. Spoj prema zahtjevu 1, naznačen time, da je to 6-(5-metil-1H-pirazol-4-il)-2-[(2S)-piperidin-2-il]tieno[3,2-d]pirimidin-4(3H)-on, ili njegova sol.
7. Spoj prema zahtjevu 1, naznačen time, da je to 2-(7-azabiciklo[2.2.1]hept-1-il)-6-(5-metil-1H-pirazol-4-il)tieno[3,2-d]pirimidin-4(3H)-on, ili njegova sol.
8. Spoj prema zahtjevu 1, naznačen time, da je to 6-(5-metil-1H-pirazol-4-il)-2-[(2S)-1,2,3,6-tetrahidropiridin-2-il]tieno[3,2-d]pirimidin-4(3H)-on, ili njegova sol.
9. Spoj prema zahtjevu 1, naznačen time, da je to 2-[(2S)-piperidin-2-il]-6-[5-(trifluorometil)-1H-pirazol-4-il]tieno[3,2-d]pirimidin-4(3H)-on, ili njegova sol.
10. Spoj prema zahtjevu 1, naznačen time, da je to 2-[(2S)-1-azabiciklo[2.2.2]okt-2-il]-6-(5-metil-1H-pirazol-4-il)tieno[3,2-d]pirimidin-4(3H)-on, ili njegova sol.
11. Lijek, naznačen time, da obuhvaća spoj prema zahtjevu 1, ili njegovu sol.
12. Spoj prema zahtjevu 1 ili njegova sol, naznačen time, da se upotrebljava u profilaksi ili liječenju raka.
13. Spoj prema zahtjevu 1, naznačen time, da spoj ili njegova sol je hidrat.
14. Spoj prema zahtjevu 4, naznačen time, da R2 je 1-azabiciklo[2.2.2]oktanil, ili njegova sol.
15. Spoj prema zahtjevu 14, naznačen time, da R1 je metilna, etilna ili trifluorometilna skupina, ili njihova sol.
16. Spoj prema zahtjevu 1, naznačen time, da spoj je tautomer izomer predstavljen s parcijalnom strukturom sljedeće formule:
17. Spoj prema zahtjevu 1, naznačen time, da spoj je tautomer izomer predstavljen s parcijalnom strukturom sljedeće formule:
18. Spoj prema zahtjevu 10, naznačen time, da spoj je tautomer izomer predstavljen s parcijalnom strukturom sljedeće formule:
pri čemu R1 je metil na poziciji 5, ili njegova sol.
19. Spoj prema zahtjevu 10, naznačen time, da spoj je tautomer izomer predstavljen s parcijalnom strukturom sljedeće formule:
pri čemu R1 je metil na poziciji 3, ili njegova sol.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010031899 | 2010-02-17 | ||
| JP2010131950 | 2010-06-09 | ||
| EP11744685.6A EP2540728B1 (en) | 2010-02-17 | 2011-02-16 | Heterocyclic compound |
| PCT/JP2011/053303 WO2011102399A1 (ja) | 2010-02-17 | 2011-02-16 | 複素環化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190947T1 true HRP20190947T1 (hr) | 2019-07-26 |
Family
ID=44482985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190947TT HRP20190947T1 (hr) | 2010-02-17 | 2019-05-23 | Heterociklički spoj |
Country Status (37)
| Country | Link |
|---|---|
| US (6) | US8722660B2 (hr) |
| EP (2) | EP2540728B1 (hr) |
| JP (1) | JP5689454B2 (hr) |
| KR (1) | KR101735868B1 (hr) |
| CN (1) | CN102844320B (hr) |
| AU (1) | AU2011216404B2 (hr) |
| BR (1) | BR112012020311B1 (hr) |
| CA (1) | CA2790284C (hr) |
| CL (1) | CL2012002250A1 (hr) |
| CO (1) | CO6592104A2 (hr) |
| CR (1) | CR20120448A (hr) |
| CY (1) | CY1121792T1 (hr) |
| DK (1) | DK2540728T3 (hr) |
| DO (1) | DOP2012000224A (hr) |
| EA (1) | EA020724B1 (hr) |
| EC (1) | ECSP12012160A (hr) |
| ES (1) | ES2733221T3 (hr) |
| GE (1) | GEP20146202B (hr) |
| HR (1) | HRP20190947T1 (hr) |
| HU (1) | HUE043514T2 (hr) |
| IL (1) | IL221442A0 (hr) |
| LT (1) | LT2540728T (hr) |
| MA (1) | MA34064B1 (hr) |
| ME (1) | ME03410B (hr) |
| MX (1) | MX353500B (hr) |
| MY (1) | MY164776A (hr) |
| NZ (1) | NZ602089A (hr) |
| PE (1) | PE20130184A1 (hr) |
| PH (1) | PH12012501650B1 (hr) |
| PL (1) | PL2540728T3 (hr) |
| PT (1) | PT2540728T (hr) |
| RS (1) | RS58796B1 (hr) |
| SG (1) | SG183304A1 (hr) |
| SI (1) | SI2540728T1 (hr) |
| SM (1) | SMT201900385T1 (hr) |
| TN (1) | TN2012000401A1 (hr) |
| WO (1) | WO2011102399A1 (hr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013003358A2 (pt) * | 2010-08-11 | 2016-07-12 | Millennium Pharm Inc | heteroaris e seus usos |
| WO2015115355A1 (ja) | 2014-01-31 | 2015-08-06 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| TW201620879A (zh) | 2014-04-28 | 2016-06-16 | 杜邦股份有限公司 | 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑 |
| US10174032B2 (en) * | 2014-05-05 | 2019-01-08 | Signalrx Pharmaceuticals, Inc. | Heterocyclic compound classes for signaling modulation |
| EP3858996B1 (en) | 2015-12-07 | 2022-08-03 | Zymergen Inc. | Microbial strain improvement by a htp genomic engineering platform |
| CA3008171A1 (en) | 2015-12-22 | 2017-06-29 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| CN108779126B (zh) * | 2016-03-28 | 2021-07-16 | 武田药品工业株式会社 | 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3，2-d]嘧啶-4(3h)-酮半水合物的结晶形式 |
| EA035560B1 (ru) * | 2016-07-28 | 2020-07-07 | Такеда Фармасьютикал Компани Лимитед | Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она |
| ES2877140T3 (es) | 2016-11-08 | 2021-11-16 | Cancer Research Tech Ltd | Derivados de pirimidinona como inhibidores de Cdc7 |
| EP3589747B1 (en) | 2017-03-01 | 2021-05-19 | Takeda Pharmaceutical Company Limited | Method of predicting effects of cdc7 inhibitor |
| WO2018217439A1 (en) * | 2017-05-21 | 2018-11-29 | Zhang Hai Jun | Substituted [5,6]cyclic-4(3h)-pyrimidinones as anticancer agents |
| EP3642209B1 (en) | 2017-06-21 | 2023-11-29 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN111989331B (zh) * | 2018-04-02 | 2024-04-12 | 武田药品工业株式会社 | 2-[(2S)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1H-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3H)-酮的合成方法 |
| TWI846703B (zh) | 2018-06-19 | 2024-07-01 | 日商武田藥品工業股份有限公司 | 癌症治療方法 |
| IL280130B2 (en) * | 2018-07-19 | 2024-11-01 | Takeda Pharmaceuticals Co | Pharmaceutical compositions with a cdc7 inhibitor |
| MX2021014629A (es) * | 2019-05-30 | 2022-02-23 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Compuestos tetraciclicos como inhibidores de cdc7. |
| EP3999050A2 (en) | 2019-07-19 | 2022-05-25 | Takeda Pharmaceutical Company Limited | Combination therapy for cancer treatment |
| EP4006036A4 (en) * | 2019-08-20 | 2022-09-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TETRACYCLIC COMPOUND USED AS A CDC7 INHIBITOR |
| WO2021113492A1 (en) | 2019-12-06 | 2021-06-10 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| CN116490507A (zh) * | 2020-09-10 | 2023-07-25 | 薛定谔公司 | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
| KR20230116005A (ko) * | 2020-11-30 | 2023-08-03 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Cdc7 억제제로 사용되는 염 형태 및 이의 결정 형태 |
| CN112661770B (zh) * | 2020-12-24 | 2022-11-08 | 南京正济医药研究有限公司 | 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法 |
| EP4288050A1 (en) | 2021-02-08 | 2023-12-13 | Takeda Pharmaceutical Company Limited | Combination therapy for cancer treatment |
| TW202300150A (zh) * | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| WO2023064879A1 (en) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4196207A (en) * | 1977-05-23 | 1980-04-01 | Ici Australia Limited | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks |
| DE19644228A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
| JP2002105081A (ja) | 2000-07-28 | 2002-04-10 | Nikken Chem Co Ltd | 新規チオフェンニ環化合物 |
| WO2002026745A1 (fr) | 2000-09-29 | 2002-04-04 | Nippon Soda Co., Ltd. | Composes de thienopyrimidine et leurs sels et procede de preparation |
| US6503914B1 (en) | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| AU2002305205A1 (en) | 2001-04-20 | 2002-11-05 | Jingrong Cao | 9-deazaguanine derivatives as inhibitors of gsk-3 |
| ATE323702T1 (de) | 2002-08-06 | 2006-05-15 | Astrazeneca Ab | Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität |
| WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| KR101186678B1 (ko) * | 2003-06-11 | 2012-09-27 | 젠션 리미티드 | 포타슘 채널 억제제로서의 티에노피리미딘 유도체 |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7279575B2 (en) | 2003-08-08 | 2007-10-09 | Pfizer Italia S.R.L. | Pyrimidylpyrrole derivatives active as kinase inhibitors |
| CA2534496A1 (en) * | 2003-08-08 | 2005-02-17 | Ermes Vanotti | Pyrimidylpyrrole derivatives active as kinase inhibitors |
| CN1989131A (zh) * | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
| EP2495324B1 (en) | 2004-04-09 | 2015-03-04 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| US20080102068A1 (en) | 2005-01-19 | 2008-05-01 | Coleman Paul J | Mitotic Kinesin Inhibitors |
| US20080221107A1 (en) | 2005-07-15 | 2008-09-11 | Astrazeneca Ab | Therapeutic Agents |
| CA2621181C (en) | 2005-08-30 | 2011-04-19 | Asahi Kasei Pharma Corporation | 5-isoquinolinesulfonamide compounds |
| FI20055498A0 (fi) | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
| US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
| US7618982B2 (en) * | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
| KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| US20090030196A1 (en) | 2006-12-29 | 2009-01-29 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| TW200836743A (en) | 2007-01-29 | 2008-09-16 | Xenon Pharmaceuticals Inc | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| WO2009001214A2 (en) | 2007-06-28 | 2008-12-31 | Pfizer Products Inc. | Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists |
| US20090118276A1 (en) | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
| CA2717529A1 (en) | 2008-03-11 | 2009-09-17 | Cellzome Limited | Sulfonamides as zap-70 inhibitors |
| PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| JP2011526693A (ja) | 2008-06-26 | 2011-10-13 | ディナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 転移に関連する徴候および決定因子、ならびにそれらの使用方法 |
| US8691828B2 (en) | 2009-03-05 | 2014-04-08 | Takeda Pharmaceutical Company Limited | Thienopyrimidine as CDC7 kinase inhibitors |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| EP2475366A1 (en) | 2009-09-11 | 2012-07-18 | Bayer Pharma Aktiengesellschaft | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs |
| TW201111378A (en) | 2009-09-11 | 2011-04-01 | Bayer Schering Pharma Ag | Substituted (heteroarylmethyl) thiohydantoins |
| JO2978B1 (en) | 2009-12-21 | 2016-03-15 | ايلي ليلي اند كومباني | MGLU2 aids |
-
2011
- 2011-02-16 NZ NZ602089A patent/NZ602089A/en unknown
- 2011-02-16 LT LTEP11744685.6T patent/LT2540728T/lt unknown
- 2011-02-16 WO PCT/JP2011/053303 patent/WO2011102399A1/ja active Application Filing
- 2011-02-16 CA CA2790284A patent/CA2790284C/en active Active
- 2011-02-16 MA MA35205A patent/MA34064B1/fr unknown
- 2011-02-16 JP JP2012500632A patent/JP5689454B2/ja active Active
- 2011-02-16 GE GEAP201112855A patent/GEP20146202B/en unknown
- 2011-02-16 RS RS20190639A patent/RS58796B1/sr unknown
- 2011-02-16 ES ES11744685T patent/ES2733221T3/es active Active
- 2011-02-16 AU AU2011216404A patent/AU2011216404B2/en active Active
- 2011-02-16 MX MX2012009602A patent/MX353500B/es active IP Right Grant
- 2011-02-16 PE PE2012001253A patent/PE20130184A1/es active IP Right Grant
- 2011-02-16 PH PH1/2012/501650A patent/PH12012501650B1/en unknown
- 2011-02-16 PL PL11744685T patent/PL2540728T3/pl unknown
- 2011-02-16 KR KR1020127024086A patent/KR101735868B1/ko active IP Right Grant
- 2011-02-16 ME MEP-2019-152A patent/ME03410B/me unknown
- 2011-02-16 SM SM20190385T patent/SMT201900385T1/it unknown
- 2011-02-16 EP EP11744685.6A patent/EP2540728B1/en active Active
- 2011-02-16 BR BR112012020311-8A patent/BR112012020311B1/pt active IP Right Grant
- 2011-02-16 US US13/578,959 patent/US8722660B2/en active Active
- 2011-02-16 HU HUE11744685A patent/HUE043514T2/hu unknown
- 2011-02-16 PT PT11744685T patent/PT2540728T/pt unknown
- 2011-02-16 EP EP19168244.2A patent/EP3533797B1/en active Active
- 2011-02-16 CN CN201180019478.3A patent/CN102844320B/zh active Active
- 2011-02-16 MY MYPI2012003715A patent/MY164776A/en unknown
- 2011-02-16 SG SG2012059994A patent/SG183304A1/en unknown
- 2011-02-16 SI SI201131722T patent/SI2540728T1/sl unknown
- 2011-02-16 EA EA201290800A patent/EA020724B1/ru unknown
- 2011-02-16 DK DK11744685.6T patent/DK2540728T3/da active
-
2012
- 2012-08-09 TN TNP2012000401A patent/TN2012000401A1/en unknown
- 2012-08-14 CL CL2012002250A patent/CL2012002250A1/es unknown
- 2012-08-14 IL IL221442A patent/IL221442A0/en active IP Right Grant
- 2012-08-15 DO DO2012000224A patent/DOP2012000224A/es unknown
- 2012-08-29 CR CR20120448A patent/CR20120448A/es unknown
- 2012-09-13 CO CO12158066A patent/CO6592104A2/es active IP Right Grant
- 2012-09-17 EC ECSP12012160 patent/ECSP12012160A/es unknown
-
2014
- 2014-03-24 US US14/223,259 patent/US8921354B2/en active Active
- 2014-03-24 US US14/223,329 patent/US8933069B2/en active Active
- 2014-12-10 US US14/566,157 patent/US9388195B2/en active Active
-
2016
- 2016-06-08 US US15/176,893 patent/US9655900B2/en active Active
-
2017
- 2017-04-11 US US15/484,755 patent/US20170209452A1/en not_active Abandoned
-
2019
- 2019-05-23 HR HRP20190947TT patent/HRP20190947T1/hr unknown
- 2019-07-09 CY CY20191100721T patent/CY1121792T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190947T1 (hr) | Heterociklički spoj | |
| AU2015304883B2 (en) | Aminopyrimidinyl compounds as JAK inhibitors | |
| HRP20220127T1 (hr) | Supstituirani spoj piperidina i njegova uporaba | |
| HRP20230086T1 (hr) | Inhibitori lizin specifične demetilaze-1 | |
| ES2759246T3 (es) | Compuestos de[1,2,4]triazolo[1,5-a]pirimidinilo-7-il sustituidos como inhibidores de PDE2 | |
| HRP20191364T1 (hr) | Sik-inhibitori tipa heteroarila | |
| AU2012299080B2 (en) | Pyrimidine PDE10 inhibitors | |
| HRP20230595T1 (hr) | Inhibitori lizina specifične demetilaze-1 | |
| PE20090596A1 (es) | Imidazoles biciclicos fusionados | |
| RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
| PE20200447A1 (es) | Compuestos de biheteroarilo y usos de los mismos | |
| PE20091211A1 (es) | Derivados de pirazolopirimidina como moduladores de pde9a | |
| NZ590297A (en) | 2-Alkylamino-7,8-dihydropteridin-6(5H)-one and 2-alkylamino-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one derivatives | |
| RU2007128625A (ru) | Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 | |
| HRP20170484T1 (hr) | Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze | |
| JP2014522855A5 (hr) | ||
| HRP20150868T1 (hr) | Derivati kinolina i kinoksalina kao inhibitori kinaze | |
| PE20160751A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| WO2013066729A1 (en) | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | |
| EP3013337A1 (en) | Primary carboxamides as btk inhibitors | |
| JP2012501312A5 (hr) | ||
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| PE20110387A1 (es) | Aminotriazolo-piridinas como inhibidores de cinasa | |
| PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 |